

S/N 09/830,749

REMARKS/ARGUMENTS

Applicant respectfully requests reconsideration of the pending claims in view of the above amendments and the following remarks.

Claims 1 and 3 are pending. Claim 1 has been amended. No new matter has been inserted. Support for the feature "human" can be found in the specification at least at page 5, line 33.

Applicants take this opportunity to point out that the terms "ERp57" and "GRp58" are defined in the specification and well-known in the art. Specifically, the specification provides that:

"Chaperones include a family known as a thiol: protein disulfide oxidoreductase (TPDO). A TPDO represents a preferred chaperone of the present invention. A preferred TPDO is TPDO-Q2. TPDO-Q2 has also been called ERp57 and GRp58. As used herein, Q2 refers to any of the common names for this protein, including TPDO-Q2, ERp57, and GRp58 and all naturally occurring variant forms of this protein, including glycosylated and nonglycosylated forms." See page 5, line 34, through page 6, line 5.

In the art, ERp57 is well-characterized as a thiol-disulfide oxidoreductase. See Frickel, 2004, *J. Biol. Chem.*, 279: 18277-18287. The art also provides that ERp57 and GRp58 refer to the same molecule. See Sehgal, 2003, *Acta Biochimica Polonica*, 50:583-594 at 583. Copies of these references are attached herewith for Examiner's convenience.

In light of the foregoing Amendment and Remarks, Applicant asserts the claims are in condition for allowance. Removal of all rejections and early notice of allowable claims is requested.

S/N 09/830,749

The Examiner is invited to telephone the undersigned attorney for clarification of any of these remarks or amendments, or to otherwise speed prosecution of this case.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
(612) 332-5300

Date: Aug 26, 2004

Mark T. Skoog
Mark T. Skoog
Reg. No. 40,178

MTS:MED:kf

